

Prson Gautam

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2947825/publications.pdf>

Version: 2024-02-01

32
papers

1,633
citations

448610

19
h-index

651938

25
g-index

36
all docs

36
docs citations

36
times ranked

3802
citing authors

#	ARTICLE	IF	CITATIONS
1	Concurrent Inhibition of IGF1R and ERK Increases Pancreatic Cancer Sensitivity to Autophagy Inhibitors. <i>Cancer Research</i> , 2022, 82, 586-598.	0.4	27
2	Patient-tailored design for selective co-inhibition of leukemic cell subpopulations. <i>Science Advances</i> , 2021, 7, .	4.7	28
3	Multi-modal meta-analysis of cancer cell line omics profiles identifies ECHDC1 as a novel breast tumor suppressor. <i>Molecular Systems Biology</i> , 2021, 17, e9526.	3.2	8
4	CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis. <i>Cancer Research</i> , 2021, 81, 4319-4331.	0.4	26
5	Atypical KRASG12R Mutant Is Impaired in PI3K Signaling and Macropinocytosis in Pancreatic Cancer. <i>Cancer Discovery</i> , 2020, 10, 104-123.	7.7	131
6	Leveraging multi-way interactions for systematic prediction of pre-clinical drug combination effects. <i>Nature Communications</i> , 2020, 11, 6136.	5.8	63
7	Low-Dose Vertical Inhibition of the RAF-MEK-ERK Cascade Causes Apoptotic Death of KRAS Mutant Cancers. <i>Cell Reports</i> , 2020, 31, 107764.	2.9	69
8	Systematic mapping of cancer cell target dependencies using high-throughput drug screening in triple-negative breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 3819-3832.	1.9	6
9	A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening. <i>Communications Biology</i> , 2020, 3, 42.	2.0	23
10	Multiobjective optimization identifies cancer-selective combination therapies. <i>PLoS Computational Biology</i> , 2020, 16, e1008538.	1.5	9
11	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
12	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
13	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
14	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
15	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
16	Multiobjective optimization identifies cancer-selective combination therapies. , 2020, 16, e1008538.		0
17	Network pharmacology modeling identifies synergistic Aurora B and ZAK interaction in triple-negative breast cancer. <i>Npj Systems Biology and Applications</i> , 2019, 5, 20.	1.4	32
18	Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets. <i>Cell Chemical Biology</i> , 2019, 26, 970-979.e4.	2.5	34

#	ARTICLE	IF	CITATIONS
19	Prediction of drug combination effects with a minimal set of experiments. <i>Nature Machine Intelligence</i> , 2019, 1, 568-577.	8.3	99
20	Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions. <i>Cell Chemical Biology</i> , 2018, 25, 224-229.e2.	2.5	124
21	Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma. <i>Hepatology</i> , 2018, 68, 949-963.	3.6	106
22	KRAS Suppression-Induced Degradation of MYC Is Antagonized by a MEK5-ERK5 Compensatory Mechanism. <i>Cancer Cell</i> , 2018, 34, 807-822.e7.	7.7	112
23	Consistency in drug response profiling. <i>Nature</i> , 2016, 540, E5-E6.	13.7	76
24	Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells. <i>Molecular Cancer</i> , 2016, 15, 34.	7.9	57
25	Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression. <i>Cancer Cell</i> , 2016, 29, 75-89.	7.7	191
26	Bioluminescent, Nonlytic, Real-Time Cell Viability Assay and Use in Inhibitor Screening. <i>Assay and Drug Development Technologies</i> , 2015, 13, 456-465.	0.6	57
27	Systematic Mapping of Kinase Addiction Combinations in Breast Cancer Cells by Integrating Drug Sensitivity and Selectivity Profiles. <i>Chemistry and Biology</i> , 2015, 22, 1144-1155.	6.2	22
28	Endothelial destabilization by angiotensin-2 via integrin $\alpha 1$ activation. <i>Nature Communications</i> , 2015, 6, 5962.	5.8	210
29	Rational Polypharmacology: Systematically Identifying and Engaging Multiple Drug Targets To Promote Axon Growth. <i>ACS Chemical Biology</i> , 2015, 10, 1939-1951.	1.6	58
30	Bioluminescent Cell-Based NAD(P)/NAD(P)H Assays for Rapid Dinucleotide Measurement and Inhibitor Screening. <i>Assay and Drug Development Technologies</i> , 2014, 12, 514-526.	0.6	23
31	Donor Simvastatin Treatment Prevents Ischemia-Reperfusion and Acute Kidney Injury by Preserving Microvascular Barrier Function. <i>American Journal of Transplantation</i> , 2013, 13, 2019-2034.	2.6	41
32	Phenotypic Screening Combined with Machine Learning for Efficient Identification of Breast Cancer-Selective Therapeutic Targets. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0